London Health Sciences Centre first in Canada to implant cutting edge cardioverter defibrillator
New device receives Health Canada approval after LHSC team participates in global study to prove safety and efficacy
image:
Dr. Jaimie Manlucu
view moreCredit: London Health Sciences Centre
LONDON, ON – In a Canadian first, London Health Sciences Centre (LHSC) was the first and only hospital in Canada to implant a new extravascular implantable cardioverter defibrillator (ICD) during clinical trials. The global study has led to Health Canada approval of the device following publications in New England Journal of Medicine and, most recently, Circulation, which have shown the long-term safety, efficacy and performance of the device.
In Canada, approximately 25,000 pacemakers and 7,000 ICDs are implanted each year making it essential for patients to receive the best device for their comfort and overall health.
56-year-old Ian McCulloch first heard about implantable cardiovascular defibrillators when he started noticing that his heartbeat was irregular. “Several years ago, I started feeling what I thought was a heavy beat, or what was an extra or missed beat. My wife encouraged me to call my doctor, and I was referred to a cardiologist, and that led to me being asked if I wanted to be part of a study.”
Through Dr. Jaimie Manlucu, Cardiac Electrophysiologist at London Health Sciences Centre (LHSC), McCulloch was enrolled in a clinical trial for the Medtronic Aurora Extravascular ICD (EV-ICD) device, a new and innovative defibrillator that was being studied for current and future cardiac patients. Dr. Manlucu, also a scientist at London Health Sciences Centre Research Institute (LHSCRI), was a key member of the International Steering Committee and site Principal Investigator on the pivotal trial
A total of 356 patients participated in this study across 17 countries and 46 medical centres worldwide, demonstrating the safety of the EV-ICD implantation procedure and its effectiveness in treating life-threatening arrhythmias.
“LHSC and some of my senior partners have had a significant role in helping develop the technology that we see in the defibrillators that we use day-to-day", says Dr. Manlucu. “I’ve been able to see this from the preliminary stages all the way through to the trials. It’s exciting to be part of the next generation helping to continue forward that partnership and effort in developing this technology.”
Unlike traditional devices, this new device is implanted outside the vascular system and heart, providing life-saving arrhythmia treatment. The smaller battery and placement in the body offers better comfort and care for the patient and reduces the frequency of subsequent battery replacement procedures.
Most standard defibrillator devices are typically inserted within the vascular system and are much larger and can sometimes cause discomfort. Dr. Manlucu notes that advancements in medical technology mean that many patients now outlive their devices, which leads to replacements or battery changes.
“We have provided feedback that has guided the device’s development from the early stages to its current use across Canada,” says Dr. Manlucu. “Seeing the device evolve through clinical trials to now helping patients is very exciting.”
Although the procedure took place in 2021, Dr. Manlucu notes that McCulloch's ability to maintain his daily routine as a young and active individual serves as additional proof of the success of both the procedure and device.
Health Canada approved the new device earlier this year, and LHSC has already performed six procedures using it.
For McCulloch, he admits it is an honour to be the first in Canada to receive this device, but mostly feels fortunate that he was able to have this done when he did. “It makes me feel proud! I’m glad to hear that a few more people have been able to do this now and I hope future patients have just as much success as I have.”
McCulloch adds that he feels he has a new lease on life. “I can play volleyball or basketball pickup games and have no restrictions or mobility issues. I feel great!”
-30-
About London Health Sciences Centre
With roots going back a century and a half, London Health Sciences Centre (LHSC) is an award-winning, research-intensive acute tertiary and quaternary teaching hospital, one of only 14 such hospitals in Ontario. LHSC is also home to Children’s Hospital, one of just four acute tertiary care paediatric hospitals in the province. Our unique place in the health system positions us well to inform and advise on provincial, national and international health policy. We are the cornerstone of care for many specialized programs and services in Western Ontario. And, as a major provider of emergency care and through our community hospital mission, we also care for the more than 400,000 people who call London home as well as many in surrounding communities. With Ontario’s health system continuing its transformation, LHSC has an opportunity to inform it and to place itself at the locus of the regionalized health system by virtue of its size, specialized capabilities, research and education capacity and its current regional footprint. LHSC’s formal relationship and strong bond with Western University provide a mechanism for collaboration to enable the delivery of high-quality care through a process of continuous learning and research. At its core, the affiliation is a reciprocal relationship that leverages the learning, teaching and care environments of both Western University and LHSC. LHSC is a 15,000-person strong team of physicians, staff and volunteers – collaborators, innovators and pioneers, meeting the care needs of those we serve and charting a course for the future.
After-hours assistance: Call LHSC Switchboard at 519-685-8500 and ask to page the communicator on-call.
Visit the LHSC media web page.
Like us on Facebook at London Health Sciences Centre (LHSC), follow us on Twitter @LHSCCanada and watch us on YouTube at LHSCCanada.
Method of Research
Randomized controlled/clinical trial
Subject of Research
People
No comments:
Post a Comment